Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
WAYNE, Pa., April 08, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
Talos Energy director Barbara J. Faulkenberry files initial beneficial ownership statement
Talos Energy director Barbara J. Faulkenberry filed an initial Form 3 statement dated Oct. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talos Energy Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418248), on October 08, 2026, and is solely responsible for the information contained therein.
Algorand’s quantum push meets AI payments – Can ALGO’s 17% rally last?
Crypto prices
More
